Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.
These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).
Aspire Pharma CEO Richard Condon described their latest acquisition as “a strategic move that not only strengthens our portfolio but also supports our central mission to meet patient needs, in terms of enhancing supply and access to essential, affordable, medicines.”
“By integrating these important products into our existing portfolio, we are reaffirming our commitment to supporting patient care by offering true value to the NHS, payors and healthcare professionals.”
The agreement will see Aspire Pharma take on the existing inventory of the acquired products, along with UK distribution rights.
In 2021, Aspire Pharma became majority-owned by an affiliate of H.I.G. Capital, a leading global alternative investment firm, in 2021.
The company aims to make a difference to the lives of patients through the development and supply of innovative products and medicines.
![Potential Side Effects of Mounjaro [What You Need to Know]](https://www.pharmacy.biz/media-library/image.jpg?id=54516976&width=1245&height=700&quality=90&coordinates=0%2C29%2C0%2C29)
